-Frontline Is there a shift in the attitude of Kerala society towards the value of daughters? Is son preference spreading in a State once known to be above extreme gender bias? A recent study on child sex ratio generates more questions than it answers. By R. KRISHNAKUMAR in Thiruvananthapuram ABORTION of female foetuses after parents learn of their gender using medical diagnostic techniques is believed to be one of the central reasons...
More »SEARCH RESULT
Total Matching Records found : 2379
Illusory rights -Venkitesh Ramakrishnan and Ajoy Ashirwad Mahaprashasta
-Frontline PESA, which is seen as an enabling law for tribal self-governance, is violated brazenly by both the Union government and State governments in the name of development. SINCE October 2012, the Ministry of Rural Development of the United Progressive Alliance (UPA) government has apparently been engaged in an exercise to evolve a "National Land Reforms Policy". Over these months, the Ministry wrote to various State governments, highlighting the importance of...
More »Landmark verdict -V Venkatesan
-Frontline The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...
More »Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »
